JP6274542B2 - 抗cd4抗体を有効成分とする抗がん剤の治療効果を判定する方法 - Google Patents
抗cd4抗体を有効成分とする抗がん剤の治療効果を判定する方法 Download PDFInfo
- Publication number
- JP6274542B2 JP6274542B2 JP2016562649A JP2016562649A JP6274542B2 JP 6274542 B2 JP6274542 B2 JP 6274542B2 JP 2016562649 A JP2016562649 A JP 2016562649A JP 2016562649 A JP2016562649 A JP 2016562649A JP 6274542 B2 JP6274542 B2 JP 6274542B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cells
- immune checkpoint
- expression
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
- G01N2333/70564—Selectins, e.g. CD62
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70585—CD44
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70589—CD45
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Ecology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
(1) 少なくとも1種の免疫チェックポイント受容体、
(2) CD8、並びに
(3) CD44及びCD45ROからなる群より選択される少なくとも1種の細胞表面分子
の、T細胞上での発現を調べることを含み、前記(1)の免疫チェックポイント分子が陽性であり、CD8陽性であり、かつ、CD44高発現及び/又はCD45RO高発現であるT細胞集団の誘導が、前記患者において前記抗がん剤が治療効果を現していることを示す、方法を提供する。
(1) 少なくとも1種の免疫チェックポイント受容体
(2) CD8
(3) CD44及びCD45ROからなる群より選択される少なくとも1種の細胞表面分子
(a) 患者由来試料のフローサイトメトリー解析
(b) 抗CD8抗体を固定化した支持体を用いて患者由来試料中のCD8+ 細胞を捕捉、洗浄の後、測定対象の細胞表面分子に対する複数の抗体にそれぞれ異なるシグナルを発する標識物質を結合させた複数の標識抗体と同時に反応させ、シグナルを区別して同時に測定・解析を行なう。
(c) 患者由来試料をプロテアーゼ等の適当な酵素で前処理して細胞表面分子をステム部分から切断し、遊離した細胞表面分子群をマルチプルELISAにて測定する。
(d) 細胞表面分子のmRNAをRT-PCRにてマルチプレックス測定する。
(i) 高い細胞傷害活性を有する抗CD4抗体
(ii) 細胞毒成分が結合された、抗CD4抗体又はその抗原結合性断片
WO 2010/074266に記載された方法により、ADCC活性が増強された抗ヒトCD4ヒト化抗体IT1208(可変領域としてWO 2010/074266に記載のHV2及びLV0を含む、サブタイプはIgG1)を作製した。Biacore T100を用いて測定された抗体結合活性はKD(nM)<0.009であり、高い結合活性を有していた。
C57BL/6系統マウス(雌、7週齢)の右側腹部にマウスメラノーマ細胞株B16F10(5x105 cells/mouse)を皮下移植した後、下記の通りに抗体投与を行なった(Day0=がん細胞移植日)。
その後 Prolong Gold reagent (Life Technologies)で包埋し、SP5 共焦点顕微鏡 (Leica Microsystems)で免疫染色像を観察した。
C57BL/6系統マウス(雌、7週齢)の右側腹部にマウスメラノーマ細胞株B16F10(5x105 cells/mouse)を皮下移植した後、下記の通りに抗体投与を行なった(Day0=がん細胞移植日)。
TNF-α(Tnf)、IFN-γ(Ifng)、Cxcl10、Cd274、Fasl、Prf1、グランザイム(Gzmb)
Claims (13)
- 抗CD4抗体を有効成分とする抗がん剤、抑制性の免疫チェックポイント分子に対するアンタゴニストを有効成分とする抗がん剤、及び共刺激性の免疫チェックポイント分子に対するアゴニストを有効成分とする抗がん剤から選択される少なくとも1種の抗がん剤によるがん療法の治療効果を試験する方法であって、前記少なくとも1種の抗がん剤が投与された患者由来の試料を用いて、
(1) 少なくとも1種の免疫チェックポイント受容体、
(2) CD8、並びに
(3) CD44及びCD45ROからなる群より選択される少なくとも1種の細胞表面分子
の、T細胞上での発現を調べることを含み、前記(1)の免疫チェックポイント分子が陽性であり、CD8陽性であり、かつ、CD44高発現及び/又はCD45RO高発現であるT細胞集団の誘導が、前記患者において前記抗がん剤が治療効果を現していることを示す、方法。 - 前記(1)が、PD-1、CD137及びTIM-3からなる群より選択される少なくとも1種である、請求項1記載の方法。
- CD45RAのT細胞上での発現を調べることをさらに含み、前記T細胞集団はCD45RA陰性である、請求項1又は2記載の方法。
- CD62LのT細胞上での発現を調べることをさらに含み、前記T細胞集団はCD62L低発現である、請求項1ないし3のいずれか1項に記載の方法。
- CCR7のT細胞上での発現を調べることをさらに含み、前記T細胞集団はCCR7陰性である、請求項1ないし4のいずれか1項に記載の方法。
- 前記試料が血液試料である、請求項1ないし5のいずれか1項に記載の方法。
- フローサイトメトリー解析により前記発現解析が行われる、請求項1ないし6のいずれか1項に記載の方法。
- 抗CD4抗体を有効成分とする抗がん剤は、高い細胞傷害活性を有する抗CD4抗体、又は細胞毒成分を結合させた抗CD4抗体若しくはその抗原結合性断片を有効成分として含有する抗がん剤である、請求項1ないし7のいずれか1項に記載の方法。
- 抑制性の免疫チェックポイント分子は、PD-1、CTLA-4、LAG-3、TIM-3、BTLA、PD-L1、PD-L2、CD80、CD86、GAL9、及びHVEMからなる群より選択される少なくとも1種であり、共刺激性の免疫チェックポイント分子は、CD137、OX40、GITR、CD137L、OX40L、及びTNFSF18からなる群より選択される少なくとも1種である、請求項1ないし8のいずれか1項に記載の方法。
- 前記アンタゴニスト及び前記アゴニストが免疫チェックポイント分子に対する抗体である、請求項1ないし9のいずれか1項に記載の方法。
- 免疫チェックポイント分子に対する抗体は、アンタゴニスト性抗PD-1抗体、抗PD-L1抗体、抗PD-L2抗体、アゴニスト性抗CD137抗体、アゴニスト性抗OX40抗体、及びアンタゴニスト性抗CTLA-4抗体からなる群より選択される少なくとも1種である、請求項10記載の方法。
- 抗CD4抗体を有効成分とする抗がん剤によるがん療法の治療効果を試験する方法である、請求項1ないし8のいずれか1項に記載の方法。
- 抗CD4抗体を有効成分とする抗がん剤と、免疫チェックポイント分子に対する抗体を有効成分とする抗がん剤の少なくとも1種との併用によるがん療法の治療効果を試験する方法である、請求項1ないし11のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014243858 | 2014-12-02 | ||
JP2014243858 | 2014-12-02 | ||
PCT/JP2015/083855 WO2016088791A1 (ja) | 2014-12-02 | 2015-12-02 | 抗cd4抗体を有効成分とする抗がん剤の治療効果を判定する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2016088791A1 JPWO2016088791A1 (ja) | 2017-11-02 |
JP6274542B2 true JP6274542B2 (ja) | 2018-02-07 |
Family
ID=56091731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016562649A Active JP6274542B2 (ja) | 2014-12-02 | 2015-12-02 | 抗cd4抗体を有効成分とする抗がん剤の治療効果を判定する方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10746726B2 (ja) |
EP (1) | EP3229025B1 (ja) |
JP (1) | JP6274542B2 (ja) |
ES (1) | ES2744936T3 (ja) |
WO (1) | WO2016088791A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3102233A4 (en) | 2014-02-05 | 2017-11-22 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
EP3156072B1 (en) | 2014-06-11 | 2020-08-19 | IDAC Theranostics, Inc. | Method for reducing side effects of immune checkpoint control agent |
US20210033599A1 (en) * | 2018-04-26 | 2021-02-04 | Nec Corporation | Information processing apparatus, control method, and program |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100099090A1 (en) * | 2007-03-05 | 2010-04-22 | Bristol-Mayers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
US9598491B2 (en) * | 2008-11-28 | 2017-03-21 | Emory University | Methods for the treatment of infections and tumors |
ES2602459T3 (es) * | 2008-12-26 | 2017-02-21 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-CD4 |
US20150273056A1 (en) * | 2012-10-12 | 2015-10-01 | The Brigham And Women's Hospital, Inc. | Enhancement of the immune response |
RU2701378C2 (ru) * | 2013-03-15 | 2019-09-26 | Дженентек, Инк. | Биомаркеры и способы лечения связанных с pd-1 и pd-l1 состояний |
-
2015
- 2015-12-02 WO PCT/JP2015/083855 patent/WO2016088791A1/ja active Application Filing
- 2015-12-02 ES ES15866302T patent/ES2744936T3/es active Active
- 2015-12-02 JP JP2016562649A patent/JP6274542B2/ja active Active
- 2015-12-02 US US15/532,465 patent/US10746726B2/en active Active
- 2015-12-02 EP EP15866302.1A patent/EP3229025B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3229025B1 (en) | 2019-07-17 |
WO2016088791A1 (ja) | 2016-06-09 |
US10746726B2 (en) | 2020-08-18 |
EP3229025A4 (en) | 2018-04-25 |
EP3229025A1 (en) | 2017-10-11 |
ES2744936T3 (es) | 2020-02-26 |
US20170328887A1 (en) | 2017-11-16 |
JPWO2016088791A1 (ja) | 2017-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108780084B (zh) | 预测细胞因子释放综合征的生物标志物 | |
JP2022033929A (ja) | 養子細胞療法を用いてb細胞悪性腫瘍を処置するための方法 | |
US20220008477A1 (en) | Methods and combinations for treatment and t cell modulation | |
US11564946B2 (en) | Methods associated with tumor burden for assessing response to a cell therapy | |
EP3548084B1 (en) | Methods for determining car-t cells dosing | |
JP2021502343A (ja) | 細胞療法とガンマセクレターゼ阻害剤との組み合わせ | |
US20210198372A1 (en) | Methods for dosing and for modulation of genetically engineered cells | |
US20190298772A1 (en) | Combination therapy of a t cell-based therapy and a btk inhibitor | |
JP2020516248A (ja) | 前立腺特異的膜抗原(psma)またはその改変型を発現する操作された細胞および関連方法 | |
KR20230156808A (ko) | Car-t 세포의 조절 방법 | |
JP2022513685A (ja) | 養子細胞療法を用いた処置のための方法 | |
JP2019513400A (ja) | エクスビボのbite活性化t細胞 | |
EP3325967B1 (en) | Methods for detecting tissue infiltrating nk cells | |
WO2019222188A1 (en) | Methods of treating cancer | |
US20210069246A1 (en) | Combination therapy using adoptive cell therapy and checkpoint inhibitor | |
JP2020523018A (ja) | がんの処置のための腫瘍反応性ヒトt細胞の同定のためのcd39およびcd103の使用 | |
JP6274542B2 (ja) | 抗cd4抗体を有効成分とする抗がん剤の治療効果を判定する方法 | |
US20210132042A1 (en) | Methods of assessing or monitoring a response to a cell therapy | |
RU2795984C2 (ru) | Изделия и способы для лечения с использованием адоптивной клеточной терапии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20170808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170825 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171013 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20171013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171013 |
|
TRDD | Decision of grant or rejection written | ||
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20171129 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171212 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171227 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6274542 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |